Table 2.
Growth modulation index by patient subgroup for patients with metastatic disease (n = 53).
| Subgroup | GMI, n (% of Each Subgroup) | ||
|---|---|---|---|
| <1 | 1–1.33 | ≥1.33 | |
| Sex | |||
| Male (n = 22) | 4 (18) | 2 (9) | 16 (73) |
| Female (n = 31) | 11 (35) | 1 (3) | 19 (61) |
| Age group | |||
| Adult (≥18 years) (n = 42) | 14 (33) | 2 (5) | 26 (62) |
| Pediatric (<18 years) (n = 11) | 1 (9) | 1 (9) | 9 (82) |
| ECOG performance status | |||
| 0 (n = 22) | 5 (23) | 2 (9) | 15 (68) |
| 1 (n = 23) | 9 (39) | 1 (4) | 13 (57) |
| 2 (n = 8) | 1 (13) | 0 | 7 (88) |
| NTRK gene | |||
| NTRK1 (n = 29) | 8 (28) | 3 (10) | 18 (62) |
| NTRK2 (n = 2) | 1 (50) | 0 | 1 (50) |
| NTRK3 (n = 22) | 6 (27) | 0 | 16 (73) |
| Lines of prior therapy | |||
| 1 (n = 13) | 2 (15) | 0 | 11 (85) |
| 2 (n = 16) | 7 (44) | 2 (13) | 7 (44) |
| ≥3 (n = 24) | 6 (25) | 1 (4) | 17 (71) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; GMI, growth modulation index; NTRK, neurotrophic tyrosine receptor kinase.